Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
Celcuity Inc. (CELC), a biopharmaceutical company, filed this Current Report on Form 8-K on September 9, 2025. The filing details a material definitive agreement involving the amendment of its existing credit facility with Oxford Finance LLC and other lenders.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring and liquidity enhancements rather than operational financial performance metrics such as revenue or profit, which are not provided in this document.
- Immediate Funding: $30.0 million Term D Loan disbursed immediately upon achievement of a milestone.
- Term E Loan: Increased from $50.0 million to up to $100.0 million. Drawdown is contingent on FDA approval of gedatolisib for second-line wild-type advanced breast cancer.
- Term F Loans: Three new loans of $40.0 million each added. Drawdown is contingent on achieving specific trailing three-month product revenue thresholds.
- Term G Loan: Replaced a prior $45.0 million facility with a new $150.0 million loan, available at the lenders' sole discretion.
- Amendment Fee: $50,000 paid to lenders at closing.
- Non-Utilization Fees: Set at 3.0% of applicable unfunded commitments for Term E and Term F loans.
- Maturity Date: Extended to November 1, 2029.
Material Changes Versus Prior Period
The Third Amendment significantly altered the company's capital structure compared to the prior Amended and Restated Loan Agreement:
- Replaced Innovatus with Oxford as the collateral agent.
- Recognized the achievement of the Term D Milestone, triggering immediate funding.
- Expanded total potential borrowing capacity through increased Term E limits and the addition of new Term F and Term G facilities.
- Extended the maturity timeline for all term loans.
Guidance, Outlook, and Unusual Items
Equity Issuance: In connection with the amendment, the company issued warrants to purchase an aggregate of 50,537 shares of common stock to Innovatus, Oxford, and affiliates. These warrants are exercisable on a cashless basis through the tenth anniversary of the Term D Loan funding date.
Regulatory Disclosure: The company issued a press release regarding this amendment on September 9, 2025, which is furnished as an exhibit but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Risks and Contingencies: Access to the majority of the new funding ($100M Term E, $120M Term F, $150M Term G) is strictly contingent upon future regulatory approvals (FDA) or commercial performance (revenue thresholds), introducing execution risk.
Investor Verification Checklist
- Verify the specific definition of the "Term D Milestone" achieved to trigger the $30.0 million disbursement.
- Confirm the exact revenue thresholds required to draw down the three $40.0 million Term F Loans.
- Review the full text of the Third Amendment (Exhibit 10.1) for covenants and conditions precedent not summarized here.
- Assess the dilution impact of the 50,537 warrants issued to lenders.
- Monitor the status of the FDA approval for gedatolisib in second-line wild-type advanced breast cancer to determine eligibility for the Term E Loan.